Back
BIO
Biome Australia Limited
π¦πΊ ASX
ποΈ CONSUMER
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
+ 41.15%
Annual Growth
4 years average annual capital growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
34
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Biome Australia Ltd. engages in the research, development, manufacture, and distribution of evidence-based products linking the gut and human health. The firm develops, licenses, commercializes and markets evidence-based live biotherapeutics (probiotics) and complementary medicines. The company develops, manufactures, and distributes evidence-based products linking the gut and human health through the Company owned brands, such as Activated Nutrients and Activated Probiotics. Activated Nutrients offers a range of completely organic, plant-based, all in-one nutritional products. Activated Probiotics offers a range of clinically backed precision probiotics. Activated Probiotics provides live biotherapeutic products clinically proven to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome. Activated Probiotics products include Biome Acne Probiotic, Biome Baby Probiotic, Biome Eczema Probiotic, Biome Her Probiotic, among others.
π Performance
Price History
+155.00%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.51
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in BIO
34
π Total Capital Earnings
$-807.043
π Average investment frequency
31 weeks
π΅ Average investment amount
$1,352
β° Last time a customer invested in BIO
1 hours
BIO investor breakdown
π΅ Income of investors
More than 200k
8%
150k - 200k
100k - 150k
50k - 100k
42%
Less than 50k
45%
πΆ Age of investors
18 - 25
18%
26 - 34
24%
35 - 90
59%
π Legal gender of investors
Female
47%
Male
53%
Pearlers who invest in BIO also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 21916.72m in AUM and 303 holdings. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
8.98%
π Share price
$110.17 AUD
π HIGH PRICE GROWTH
π§± MATERIALS
π¦πΊ AUSTRALIA
β³οΈ DIVERSIFIED
πΈ FINANCIALS
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
16.63%
π Share price
$147.17 AUD
π GLOBAL
π€ TECHNOLOGY
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
π Performance (5Yr p.a)
21.46%
π Share price
$65.85 AUD
π HIGH PRICE GROWTH
πΊπΈ UNITED STATES
Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
π Performance (5Yr p.a)
133.81%
π Share price
$13.92 AUD
𧬠BIOTECHNOLOGY
DroneShield Ltd. engages in the development and commercialisation of hardware and software technology for drone detection and security. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-06-22. The company provides artificial intelligence-based platforms for protection against advanced threats, such as drones and autonomous systems. The company offers customers bespoke counter-drone (or counter-UAS) and electronic warfare solutions and off-the-shelf products designed to suit a variety of terrestrial, maritime, or airborne platforms. The Companyβs products include DroneGun Tactical, DroneGun MKIII, DroneSentry, DroneSentry-C2, DroneSentry-X, RfPatrol and DroneSim among others. The DroneGun Tactical is an unmanned aerial systems (UAS) countermeasure designed for two-hand operation and long-range defeat. RfPatrol is a passive/non-emitting wearable UAS detection device. The Companyβs capabilities include C-UAS, C-UxS Training, and Electronic Warfare.
π Performance (5Yr p.a)
357.58%
π Share price
$3.12 AUD
π AEROSPACE & DEFENSE
Want more shares? Try these...